Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants

Prior treatment

• Known or suspected allergy to the investigational product or its excipients, or history of severe allergy (including any food or drug allergy).
• Body weight change \>5% within 3 months prior to screening (weight change % = \[maximum weight in 3 months - minimum weight in 3 months\] / maximum weight in 3 months x 100%).
• History of infectious disease within 4 weeks prior to screening (judged by the investigator as potentially significantly affecting safety evaluation), history of severe trauma, or history of major surgery within 3 months, or planned surgery during the study period.
• Participants who have undergone dieting or weight-loss treatment within 30 days prior to the first dose, or who have experienced major changes in lifestyle habits.
• Use of GLP-1 receptor agonists, weight-loss drugs, systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months before the first dose.
• Engaged in strenuous muscle exercise, high-intensity resistance training, or regular muscle-strengthening activities within 30 days before the first dose.

Other illness

• Known history of disease or comorbidity affecting skeletal muscle protein.
• At screening, the presence of active acne, pyogenic dermatosis, allergic dermatosis, inflammatory dermatosis, infectious dermatosis, unhealed skin wounds, extensive skin lesions, or skin abnormalities such as vegetations or masses, judged by the investigator as unsuitable for participation.

Lab values

• History of pancreatitis (chronic pancreatitis or idiopathic acute pancreatitis); serum amylase or lipase above the upper limit of normal.
• At screening, any laboratory test meeting any of the following criteria: a) fasting blood glucose \>6.1 mmol/L or \<3.9 mmol/L; b) alanine aminotransferase, aspartate aminotransferase, or total bilirubin \>1.5 × upper limit of normal (ULN); c) estimated glomerular filtration rate \<70 mL/min/1.73 m² (CKD-EPI equation) or urinary protein positive (1+ or above); d) fasting triglycerides ≥3.42 mmol/L (Part 1) or \>5.64 mmol/L (Part 2); e) hemoglobin \<100 g/L (females) or \<110 g/L (males); f) blood uric acid (UA) \>540 μmol/L.
• At screening, 12-lead electrocardiogram showing heart rate \<50 bpm or \>100 bpm, second-degree or third-degree atrioventricular block, long QT syndrome, or QTcF \>460 ms (female) or \>450 ms (male), or other electrocardiogram abnormalities judged by the investigator as requiring pharmacological intervention.

Other

• Diagnosed with secondary overweight or obesity.

• Male or female participants aged 18 to 65 years (inclusive) at the time of signing the informed consent form (ICF); the proportion of either gender shall not be less than 1/3.
• Male participants with body weight not less than 50 kg, female participants with body weight not less than 45 kg; body mass index (BMI) within 20.0 to 40.0 kg/m\^2 (inclusive).
• Female participants must have no plans for pregnancy or egg donation from 14 days before the first dose to 6 months after the last dose and must agree to use effective contraceptive measures to avoid pregnancy; male participants must have no plans for fathering a child or sperm donation from the first dose to 6 months after the last dose and must agree to use effective contraceptive measures to avoid causing partner pregnancy.